CA

Cardiogeni Plc

Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BTBLFC12
LEI:
9845000F8F59ATZD8F92
Country:
United Kingdom
Address:
Celixir House Stratford-Upon-Avon Business & Technology Park, CV37 7GZ Stratford-Upon-Avon
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Cardiogeni Plc is a clinical-stage biotechnology company, founded by Nobel Laureate Professor Sir Martin Evans, that focuses on developing next-generation treatments for heart failure. The company specializes in regenerative medicine, utilizing a proprietary platform technology to create engineered cellular medicines. These therapies are designed to treat patients with heart failure, particularly those undergoing coronary artery bypass surgery. Cardiogeni's lead product candidate is CLXR-001. The company's mission is to become a market leader in heart failure regeneration by developing a new class of life-saving treatments.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Cardiogeni Plc. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-24 17:45
Share Issue/Capital Change
Details of Advanced Subscription & Company Update
English 21.0 KB
2025-07-24 08:00
Capital/Financing Update
£150,000 Advanced Subscription Agreement
English 14.2 KB
2025-07-02 08:00
Regulatory News Service
Appointment of corporate broker
English 11.6 KB

Automate Your Workflow. Get a real-time feed of all Cardiogeni Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cardiogeni Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Molecure S.A. Logo
Developing first-in-class small molecule drugs for cancer and inflammatory/fibrotic diseases.
Poland MOC
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany MOR
Mycodern Spolka Akcyjna Logo Poland MCD
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom N4P
Nanobiotix Logo
Developing physics-based nanotherapeutics that amplify radiotherapy to treat solid tumors.
France NANO
NanoGroup S.A. Logo
Develops nanotech medical solutions for oncology, transplantology, diagnostics, and therapy.
Poland NNG
Nattaro Labs AB Logo
Develops research-based, sustainable solutions for bed bug prevention, detection, and control.
Sweden NATTA
Neovacs Logo
Develops therapeutic vaccines for autoimmune diseases & allergies, while investing in BioTech/MedTech.
France ALNEV
Newron Pharmaceuticals S.p.A. Logo
Developing novel therapies for CNS diseases like Parkinson's and schizophrenia.
Italy NWRN
NextCell Pharma AB Logo
Develops MSC therapies for autoimmune diseases and offers private stem cell banking services.
Sweden NXTCL